Literature DB >> 25355540

Lymphomatoid granulomatosis presenting with cutaneous involvement: a case report and review of the literature.

Carolyn D Rysgaard1, Mary Seabury Stone.   

Abstract

Lymphomatoid granulomatosis (LG) is a rare Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorder presenting in middle adulthood that nearly always affects the lungs and shows cutaneous involvement in up to 50% of cases. Skin lesions are present at the time of diagnosis in roughly one-third of patients and may precede the development of lung lesions in as many as 10-15%. Recognition by both the dermatologist and dermatopathologist is therefore crucial for early and accurate diagnosis. While skin involvement is grossly and microscopically diverse, the disease most commonly presents as erythematous subcutaneous and dermal nodules showing the classic histopathologic triad of transmural lymphocytic angiitis, atypical B-lymphocytes in a polymorphous T-cell background, and necrotic foci within lymphoid aggregates. We present a case of lymphomatoid granulomatosis initially presenting with cutaneous lesions, with an accompanying review of the literature.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  dermatopathology; granulomatous inflammation; lymphoma; vasculitis

Mesh:

Substances:

Year:  2014        PMID: 25355540     DOI: 10.1111/cup.12402

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  2 in total

1.  A Literature Revision in Primary Cutaneous B-cell Lymphoma.

Authors:  R La Selva; S Alberti Violetti; C Delfino; V Grandi; S Cicchelli; C Tomasini; M T Fierro; E Berti; N Pimpinelli; P Quaglino
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

2.  Lymphomatoid Granulomatosis with Isolated Cutaneous Lesions: Prolonged Remission After DA-EPOCH Protocol

Authors:  Vineet Govinda Gupta; Ajay Gogia; Vinod Sharma; Saumyaranjan Mallick
Journal:  Turk J Haematol       Date:  2018-06-01       Impact factor: 1.831

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.